Compare Incyte Corporation (INCY) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs United Airlines Holdings Inc — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while United Airlines Holdings Inc trades at $107.51 (market cap $34.87B). The key difference: United Airlines Holdings Inc is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and United Airlines Holdings Inc for 46 Days on average.
| INCY | UAL | |
|---|---|---|
Market Cap | $22.85B | $34.87B |
Volume | 1,927,029 | 6,329,678 |
Sector | Health | Industrials |
52-Week High | $129.93 | $136.11 |
52-Week Low | $83.80 | $85.21 |
Typical Hold Time | 33 Days | 46 Days |
Enterprise Value | $18.35B | $51.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
United Airlines (UAL) trades at $107.46, down 2.46% with a bearish technical signal despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 10.1 and P/S of 0.6, supported by consistent earnings beats and improving profitability. Recent news highlights aggressive customer acquisition strategies targeting Delta's premium travelers through status-match offers and Starlink-enabled WiFi advantages.
UAL presents a compelling value opportunity with analyst consensus price target of $158.10 (47% upside) and unanimous buy/hold ratings. However, near-term headwinds include rising fuel costs, labor expenses, and technical weakness. The company's strong cash flow generation and strategic positioning for premium customer capture support long-term growth prospects despite current market pessimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
